Bristol-Myers Squibb/BMY

$48.51

0.47%
-
1D1W1MYTD1YMAX

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Ticker

BMY

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Christopher Boerner

Employees

34,100

Headquarters

Princeton, United States

BMY Metrics

BasicAdvanced
$97.85B
Market cap
12.52
P/E ratio
$3.86
EPS
0.41
Beta
$2.28
Dividend rate
4.97%
Dividend yield
$97.85B
0.41115
$70.94
$47.58
15.81M
$2.28
1.427
1.308
124.543
135.141
59.34%
10.585
12.39%
8.38%
26.53%
10.89%
12.516
2.174
3.315
12.375
3.16%
4.72%
4.97%
-2.5%
30.66%
1.91%
8.2%

What the Analysts think about BMY

Analyst Ratings

Majority rating from 27 analysts.
Hold

Price Targets

Average projection from 21 analysts.
15.34% upside
High $75.00
Low $40.00
$48.51
Current price
$55.95
Average price target

BMY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
15.35% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$11.48B
4.66%
Net income
$1.76B
-8.61%
Profit margin
15.35%
-12.68%

BMY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.13%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$2.05
$1.75
$2.00
$1.70
-
Expected
$1.97
$1.98
$1.76
$1.53
-$4.43
Surprise
3.92%
-11.43%
13.64%
11.13%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Bristol-Myers Squibb stock?

Bristol-Myers Squibb (BMY) has a market cap of $97.85B as of April 16, 2024.

What is the P/E ratio for Bristol-Myers Squibb stock?

The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 12.52 as of April 16, 2024.

Does Bristol-Myers Squibb stock pay dividends?

Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of April 16, 2024, the dividend rate is $2.28 and the yield is 4.97%. Bristol-Myers Squibb has a payout ratio of 59.34% on a trailing twelve-month basis.

When is the next Bristol-Myers Squibb dividend payment date?

The next Bristol-Myers Squibb (BMY) dividend payment is scheduled for May 01, 2024.

What is the beta indicator for Bristol-Myers Squibb?

Bristol-Myers Squibb (BMY) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Bristol-Myers Squibb stock price target?

The target price for Bristol-Myers Squibb (BMY) stock is $55.95, which is 15.34% above the current price of $48.51. This is an average based on projections from 21 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Bristol-Myers Squibb stock

Buy or sell Bristol-Myers Squibb stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing